A compound represented by the general formula (I) of the present invention, which has an EP1 receptor antagonism:[wherein A represents a benzene ring or the like Y represents a C1-6 alkylene group or the like RN represents a hydrogen atom or a C1-6 alkyl group R1 represents a hydrogen atom, a C1-6 alkyl group or the like R2 represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic group which may have a substituent, a 6-membered aromatic heterocyclic group which may have a substituent or the likeR3 represents a halogen atom, a C1-6 alkoxy group or the like R4 represents a hydrogen atom or the like and R5 represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.